个人简历

教育及工作经历 2005年9月~2009年6月 西华大学生物工程学院，本科 2009年9月~2011年9月 四川大学华西药学院，硕士生（导师：杨胜勇教授） 2011年9月~2014年6月 四川大学生物治疗国家重点实验室，博士生（导师：杨胜勇教授） 2014年7月~2015年7月 四川大学生物治疗国家重点实验室，博士后（导师：杨胜勇教授、陈宇综教授） 2015年7月~2016年8月 英国牛津大学化学研究实验室，博士后（导师：Christopher J. Schofield教授、院士） 2016年9月~至今 四川大学华西药学院，药物化学系，特聘副研究员

研究领域

主要从事药物化学、化学生物学及药物设计学等交叉学科研究工作。以创新药物研发为导向，针对临床上重要的药物靶标，发展靶标特异性药物设计新方法、药物筛选新技术、药物靶标鉴定新技术等，以发现新型先导化合物，进而开展结构优化、小分子探针等研究，并利用结构生物学、生物物理、分子生物学等技术手段阐明作用机制，以期最终获得具有临床应用前景的小分子候选化合物。

近期论文

1. Yang, L.-L.; Wang, H.-L.; Zhong, L.; Yuan, C.; Liu, S.-Y.; Yu, Z.-J.; Liu, S.; Yan, Y.-H.; Wu, C.; Wang, Y.; Wang, Z.; Yu, Y.; Chen, Q.*; Li, G.-B.*, X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells. Eur. J. Med. Chem. 2018, 155, 806-823. (IF=4.8) 2. Liu, S.; Jing, L.; Yu, Z.-J.; Wu, C.; Zheng, Y.; Zhang, E.; Chen, Q.; Yu, Y.; Guo, L.; Wu, Y.*; Li, G.-B.*, ((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies. Eur. J. Med. Chem. 2018, 145, 649-660. (IF=4.8) 3. Zhang, C.; Pu, Y.-c.; Yu, Z.-J.; Wu, C.-y.; Brem, J.; McDonough, M. A.; Schofield, C. J.; Li, G.-B.*; Wu, Y.*, Rh(iii)-Catalyzed directed C-H carbenoid coupling reveals aromatic bisphosphonates inhibiting metallo- and Serine-β-lactamases. Org. Chem. Front. 2018, 5, 1288-1292. (IF=5.45) 4. Yu, Z.-J.; Zhang, C.; Li, J.-L.; Liu, Y.-Z.; Yu, X.-L.; Guo, L.; Li, G.-B.*; Wu, Y.*, Rh(III)-Catalyzed, 1,2,3-Triazole-Assisted Directed C-H Coupling with Diazo Diphosphonates. Tetrahedron Lett. 2018, 59, 2816-2819. (IF=2.1) 5. Yu, Z.-J.; Liu, S.; Zhou, S.; Li, H.; Yang, F.; Yang, L.-L.; Wu, Y.; Guo, L.; Li, G.-B.*, Virtual target screening reveals rosmarinic acid and salvianolic acid A inhibiting metallo- and serine-β-lactamases. Bioorg. Med. Chem. Lett. 2018, 28, 1037-1042. (IF=2.4) 6. Yang, Z.; Zhang, Y.; Chen, X.; Li, W.; Li, G.-B.*; Wu, Y.*, Total Synthesis and Evaluation of B-Homo Palmatine and Berberine Derivatives as p300 Histone Acetyltransferase Inhibitors. Eur. J. Org. Chem. 2018, 2018, 1041-1052. (IF=2.9) 7. Liu, S.; Ji, S.; Yu, Z.-J.; Wang, H.-L.; Cheng, X.; Li, W.-J.; Jing, L.; Yu, Y.; Chen, Q.; Yang, L.-L.; Li, G.-B.*; Wu, Y.*, Structure-based discovery of new selective small-molecule sirtuin 5 inhibitors. Chem. Biol. Drug Des. 2018, 91, 257-268. (IF=2.3) 8. Yang, L.; Ma, X.; He, Y.; Yuan, C.; Chen, Q.; Li, G.B.*; Chen, X.*, Sirtuin 5: a review of structure, known inhibitors and clues for developing new inhibitors. Sci. China Life Sci. 2017, 60, 249-256. (IF=3.1) 9. Wang, Y.; Yu, Y.; Li, G.-B.; Li, S.-A.; Wu, C.; Gigant, B.; Qin, W.; Chen, H.; Wu, Y.; Chen, Q.; Yang, J., Mechanism of microtubule stabilization by taccalonolide AJ. Nature Communications 2017, 8, 15787. (IF=11) 10. Wang, H.-L.; Liu, S.; Yu, Z.-J.; Wu, C.; Cheng, L.; Wang, Y.; Chen, K.; Zhou, S.; Chen, Q.; Yu, Y.*; Li, G.-B.*, Interactions between sirtuins and fluorogenic small-molecule substrates offer insights into inhibitor design. RSC Adv. 2017, 7, 36214-36222. (IF=2.9) 11. Li, G.-B.*; Yu, Z.-J.; Liu, S.; Huang, L.-Y.; Yang, L.-L.; Lohans, C. T.; Yang, S.-Y., IFPTarget: A Customized Virtual Target Identification Method Based on Protein–Ligand Interaction Fingerprinting Analyses. J. Chem. Inf. Model. 2017, 57, 1640-1651. (IF=3.8) 12. Li, G.-B.; Brem, J.; Lesniak, R.; Abboud, M. I.; Lohans, C. T.; Clifton, I. J.; Yang, S.-Y.; Jimenez-Castellanos, J.-C.; Avison, M. B.; Spencer, J.; McDonough, M. A.; Schofield, C. J., Crystallographic analyses of isoquinoline complexes reveal a new mode of metallo-β-lactamase inhibition. Chem. Commun. 2017, 53, 5806-5809. (IF=6.3, Back Cover) 13. Li, G.-B.; Abboud, M. I.; Brem, J.; Someya, H.; Lohans, C. T.; Yang, S.-Y.; Spencer, J.; Wareham, D. W.; McDonough, M. A.; Schofield, C. J., NMR-filtered virtual screening leads to non-metal chelating metallo-β-lactamase inhibitors. Chem. Sci. 2017, 8, 928-937. (IF=9.0, Back Inside Cover) 14. Li, G.-B.; Huang, L.-Y.; Li, H.; Ji, S.; Li, L.-L.; Yang, S.-Y., Identification of new p300 histone acetyltransferase inhibitors from natural products by a customized virtual screening method. RSC Adv. 2016, 6, 61137-61140. (IF=2.9) 15. Li, G.-B.; Ma, S.; Yang, L.-L.; Ji, S.; Fang, Z.; Zhang, G.; Wang, L.-J.; Zhong, J.-M.; Xiong, Y.; Wang, J.-H.; Huang, S.-Z.; Li, L.-L.; Xiang, R.; Niu, D.; Chen, Y.-C.; Yang, S.-Y.*, Drug Discovery against Psoriasis: Identification of a New Potent FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor, 1-(4-((1H-Pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea, That Showed Potent Activity in a Psoriatic Animal Model. J. Med. Chem. 2016, 59, 8293-8305. (IF=6.2)